Saquinavir

This classification denotes a protease inhibitor with the molecular formula C38H50N6O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L3JE09KZ2F, chemically known as butanediamide, n1-(3-(3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1h)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (3s-(2(1r*(r*),2s*),3alpha,4aalpha,8aalpha))- but generally known as saquinavir, which bears US NIH Compound Identifier 60787. European Medicines Agency schedules Saquinavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10446MIG. The term SAQUINAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 No. 3 1994, List 34). World Health Organization schedules saquinavir in its Anatomical Therapeutic Chemical (ATC) Classification. SAQUINAVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule saquinavir under HS 29334910 and SITC 51575. As of Q4 2014, SAQUINAVIR remains the US FDA Preferred Term for this commodity. Saquinavir bears US NLM identifiers UMLS ID C0286738 and NCI Concept Code C29444. SMILES: O=C(NC(C)(C)C)C1N(CC2C(C1)CCCC2)CC(O)C(NC(=O)C(NC(=O)C1NC2C(CC1)CCCC2)CC(=O)N)CC1CCCCC1.